Using post-mortem tissues and longitudinal clinical data, we have studied alterations in cholinergic, serotonergic, glutamatergic and GABAergic neurotransmission in Alzheimer’s Disease (AD) and vascular dementia (VaD). I am especially interested in correlating neurochemical measures with behavioural, neuroimaging and neuropathological changes with the aim of identifying targets for rational receptor-based pharmacotherapeutic strategies and clinical predictors. More recently, we have begun studies of Lewy body and Parkinson disease dementias as well as tackling the neurochemistry of ‘non-classical’ systems involving purines, histamine and neuropeptides.

Click here for our latest research on dementia neurochemistry.